| Wang, Xuefei |
NCT03680261: Enriched-CRT 2017: Advanced Gastric Cancer With LN+ and LVI+, Chemotherapy vs. Chemoradiotherapy |
|
|
| Not yet recruiting | 3 | 556 | RoW | chemoradiotherapy, Study group (CRT), chemotherapy, Control group (CT) | Shanghai Zhongshan Hospital | Gastric Cancer | 09/23 | 09/23 | | |
| Recruiting | 3 | 314 | RoW | statins, Simvastatin Shu Jiangzhi is manufactured by Merchant Company20mg*14 tablets Dose group: 20 mg once a day before bed, Atorvastatin Lipitor, commonly known as Atorvastatin Calcium Tablets, 20mg*7 tablets Dose group: 10 mg once a day before bed, Atorvastatin Ale Beijing Jialin Pharmaceutical Co., Ltd. Alatorvastatin Calcium Tablets Specification and packing: 10mg*7 tablets Dose group: 10 mg once a day before bed, Dietary intervention group (control group), Dietary and motor regulation | Peking Union Medical College Hospital | Breast Cancer Female | 05/24 | 06/24 | | |
NCT04799548: A Phase II Study of TACE Plus PD-1 Antibody in the Locally Advanced Stomach Adenocarcinoma |
|
|
| Recruiting | 2 | 71 | RoW | Transcatheter Arterial Chemoembolization, Tislelizumab | Shanghai Zhongshan Hospital | Advanced Gastric Cancer | 12/24 | 01/26 | | |
NCT05095467: HIPEC-AS in Patients With Peritoneal Metastasis of the Stomach or Esophagogastric Junction |
|
|
| Not yet recruiting | 2 | 157 | NA | HIPEC, Paclitaxel injection, Paclitaxel-albumin, Tegafur-gimeracil-oteracil potassium, Surgery+HIPEC | Xuefei.Wang | Stomach Neoplasms, Peritoneal Metastases | 10/23 | 10/26 | | |
ROSETTE, NCT06468280: Synergistic Effects of PD-1 Antibody and Chemotherapy Followed by Surgery-centric Local Treatment in Patients with Limited-metastatic Gastric Cancer |
|
|
| Recruiting | 2 | 84 | RoW | Local treatment (Surgical), PD-1 Monoclonal Antibody, XELOX Chemotherapy Regimen, Local Treatment (Non-surgical) | Shanghai Zhongshan Hospital | Gastric Cancer, GastroEsophageal Cancer | 12/27 | 12/28 | | |
| Recruiting | N/A | 498 | RoW | Blood draw and blood-based biomarkers analyses | Shanghai Zhongshan Hospital, Guangzhou Burning Rock Bioengineering Ltd | Cancer | 05/22 | 09/22 | | |
| Completed | N/A | 39797 | RoW | | McMaster University, Canadian Institutes of Health Research (CIHR), McMaster Surgical Associates, National Health and Medical Research Council, Australia, Hamilton Health Sciences Corporation | Fractures or Dislocations | 11/23 | 11/23 | | |
IMPACT-GC, NCT06662110: IMmune Proteomics to Predict NeoAdjuvant Chemotherapy and ImmunoTherapy Response in Gastric Cancer |
|
|
| Recruiting | N/A | 206 | RoW | PSRscore | Shanghai Zhongshan Hospital | Gastric Cancer, Gastroesophageal Junction Cancer | 06/26 | 06/29 | | |
NCT06035016: Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2 Positive Early-stage Breast Cancer |
|
|
| Recruiting | N/A | 300 | RoW | pyrotinib combined with Capecitabine, treatment of physician's choice | Peking Union Medical College Hospital | HER2-positive Breast Cancer, Early-stage Breast Cancer | 06/27 | 06/27 | | |
NCT05203549: Consistency Between Treatment Responses in PDO Models and Clinical Outcomes in Gastric Cancer |
|
|
| Recruiting | N/A | 250 | RoW | Tumor biopsy | D1 Medical Technology (Shanghai) Co., Ltd, China, Shanghai Zhongshan Hospital | Gastric Cancer | 01/23 | 06/23 | | |
NCT05347524: Detection of Peritoneal Metastasis of Gastric Cancer by Liquid Biopsy in Peripheral Blood: A Prospective Study |
|
|
| Recruiting | N/A | 384 | RoW | Baseline blood draw and blood-based biomarkers analyses | Shanghai Zhongshan Hospital, Guangzhou Burning Rock Bioengineering Ltd | Cancer | 12/23 | 06/30 | | |
| Tang, Zhaoqing |
NCT04799548: A Phase II Study of TACE Plus PD-1 Antibody in the Locally Advanced Stomach Adenocarcinoma |
|
|
| Recruiting | 2 | 71 | RoW | Transcatheter Arterial Chemoembolization, Tislelizumab | Shanghai Zhongshan Hospital | Advanced Gastric Cancer | 12/24 | 01/26 | | |
IMPACT-GC, NCT06662110: IMmune Proteomics to Predict NeoAdjuvant Chemotherapy and ImmunoTherapy Response in Gastric Cancer |
|
|
| Recruiting | N/A | 206 | RoW | PSRscore | Shanghai Zhongshan Hospital | Gastric Cancer, Gastroesophageal Junction Cancer | 06/26 | 06/29 | | |
| Gu, Yuan |
IMPACT-GC, NCT06662110: IMmune Proteomics to Predict NeoAdjuvant Chemotherapy and ImmunoTherapy Response in Gastric Cancer |
|
|
| Recruiting | N/A | 206 | RoW | PSRscore | Shanghai Zhongshan Hospital | Gastric Cancer, Gastroesophageal Junction Cancer | 06/26 | 06/29 | | |
